DOJ’s Health Care Fraud Unit Sees Growth and Notable Results in FY 2018
Advisories | News |
DOJ’s Health Care Fraud Unit Sees Growth and Notable Results in FY 2018
January 10, 2019 The U.S. Department of Justice (DOJ) Criminal Division recently released its Fraud Section Year in Review for 2018. The Fraud Section runs three litigating units, including the… Read more »
THE VIRGINIA PRESCRIPTION MONITORING PROGRAM AS A TOOL OF ENFORCEMENT
Advisories | News |
THE VIRGINIA PRESCRIPTION MONITORING PROGRAM AS A TOOL OF ENFORCEMENT
December 19, 2018 The Virginia Prescription Monitoring Program (“PMP”) is a statewide electronic database with information on dispensed controlled substances included in Schedule II, III and IV; those in Schedule… Read more »
FDA Announces Exclusion of Three Substances from its Section 503B Bulk List
Advisories | News |
FDA Announces Exclusion of Three Substances from its Section 503B Bulk List
November 5, 2018 Drug compounding is the process of combining (two or more drugs), mixing, or altering ingredients to create a medication tailored to the needs of an individual patient.[1]… Read more »
PROTECT INITIATIVE: ADVANCING CHILDREN’S MEDICATION SAFETY
Events | News |
PROTECT INITIATIVE: ADVANCING CHILDREN’S MEDICATION SAFETY
Elizabeth Whalley Buono will be presenting “Federal and State Responses to the Opioid Epidemic” at the Center for Disease Control’s (CDC) Annual meeting of The Prevention of Overdoses and Treatment… Read more »
FDA APPROVES FINAL OPIOID ANALGESIC RISK EVALUATION AND MITIGATION STRATEGY WITH A FOCUS ON EDUCATION OF BOTH PROVIDERS AND PATIENTS
Advisories | News |
FDA APPROVES FINAL OPIOID ANALGESIC RISK EVALUATION AND MITIGATION STRATEGY WITH A FOCUS ON EDUCATION OF BOTH PROVIDERS AND PATIENTS
October 25, 2018 This past week, as part of the U.S. Food and Drug Administration’s (FDA) goal of reducing serious adverse outcomes resulting from inappropriate prescribing and misuse and abuse… Read more »
ANNUAL FDA INTER-GOVERNMENTAL WORKING MEETING REVIEWS REGULATORY PROGRESS AND ANNOUNCES NEW GUIDANCE FOR COMPOUNDING INDUSTRY
Advisories | News |
ANNUAL FDA INTER-GOVERNMENTAL WORKING MEETING REVIEWS REGULATORY PROGRESS AND ANNOUNCES NEW GUIDANCE FOR COMPOUNDING INDUSTRY
October 2, 2018 On Sept. 24, 2018, the U.S. Food and Drug Administration (FDA) convened its seventh inter-governmental working meeting as part of its commitment to maintaining close communication with… Read more »
IMPORTANT REVISIONS REGARDING CREDENTIALING REIMBURSEMENT
Advisories | News |
IMPORTANT REVISIONS REGARDING CREDENTIALING REIMBURSEMENT
9/25/2018 Credentialing physicians is frequently an arduous process that takes several months to complete and involves hours of paperwork detailing every certification, academic experience and personal background. Thankfully, for Virginia… Read more »
OPIOID BILLS WILL LIKELY RESULT IN SIGNIFICANT CHANGES IN THE WAY OPIOIDS ARE PRESCRIBED, DISPENSED AND PACKAGED
Advisories | News |
OPIOID BILLS WILL LIKELY RESULT IN SIGNIFICANT CHANGES IN THE WAY OPIOIDS ARE PRESCRIBED, DISPENSED AND PACKAGED
September 21, 2018 On Monday September 17, 2018, with almost unanimous support, the Senate passed a package of 70 bills that collectively seek to address the myriad of challenges posed… Read more »
Virginia Impact Investing Forum and Social Entrepreneurship
Events | News |
Virginia Impact Investing Forum and Social Entrepreneurship
Elizabeth Whalley Buono will be presenting Scaling the Health Economy at the “Virginia Impact Summit” hosted by the Office of Governor Northam, the Virginia Impact Investing Forum & Social Entrepreneurship… Read more »
What’s Happening in the Medicare Advantage World
Advisories | News |
What’s Happening in the Medicare Advantage World
August 23, 2018 The Medicare Advantage sector is experiencing steady growth. From the increasing number of enrolled beneficiaries, to health insurers investing in this privatized version of traditional Medicare, to… Read more »
MALPRACTICE POINTERS WHEN PRESCRIBING DRUGS FOR OFF-LABEL USES
Advisories | News |
MALPRACTICE POINTERS WHEN PRESCRIBING DRUGS FOR OFF-LABEL USES
August 21, 2018 Unlike the regulatory prohibitions against drug and device manufacturers advertising and/or promoting use of their products off-label, doctors are free to responsibly use FDA-regulated products outside of… Read more »
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39